(ran-i-bi-zoo-mab) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: monoclonal antibodies
Pregnancy Category: C


Neovascular (wet) age-related macular degeneration.Macular edema following retinal vein occlusion.Diabetic macular edema


Binds to vascular endothelial growth factor A (VEGF-A) receptor sites, preventing the binding of endogenous VEGF-A, resulting in decreased endothelial proliferation, vascular leakage and new vessel formation.

Therapeutic effects

Decreased progression of visual loss.


Absorption: Intravitreal injection results in complete local bioavailability. Very low serum levels are achieved.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 9 days (intravitreal).

Time/action profile

intravitrealunknownafter injection1 mo


Contraindicated in: Hypersensitivity; Ocular/periocular infections.
Use Cautiously in: Obstetric: Use only in pregnancy if clearly needed, use cautiously during lactation; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hemorrhage (most frequent)
  • eye pain (most frequent)
  • ↑ intraocular pressure (most frequent)
  • intraocular inflammation (most frequent)
  • vitreal floaters (most frequent)
  • endophthalmitis
  • retinal detachment


  • arterial thromboembolic events (life-threatening)


Drug-Drug interaction

↑ risk of serious intraocular inflammation with verteporfin.


Macular Degeneration

Intravitreal (Adults) 0.5 mg (0.05 mL) once monthly; after 4 mo, injections may be given every 1–3 mo.

Macular Edema Following Retinal Vein Occlusion

Intravitreal (Adults) 0.5 mg (0.05 mL) once monthly.

Diabetic Macular Edema

Intravitreal (Adults) 0.3 mg (0.05 mL) once monthly.


Solution for intravitreal injection: 0.3 mg (0.05 mL)/vial, 0.5 mg (0.05 mL)/vial

Nursing implications

Nursing assessment

  • Assess eye for signs of infection frequently during week following injection.
  • Check perfusion of optic nerve head immediately after injection, use tonometry to measure intraocular pressure prior to and 60 min following the injection.

Potential Nursing Diagnoses

Disturbed sensory perception (Indications)


  • Do not administer solutions that are discolored or contain particulate matter. Attach threaded plastic threader rod to the rubber stopper inside barrel of syringe. Do not pull back on plunger.
    • Adequate analgesia and a broad-spectrum antibiotic should be given prior to injection.
  • Intravitreal: For ophthalmic intravitreal injection only. Withdraw vial contents through a 5–micron gauge filter needle attached to a 1–cc tuberculin syringe. Discard filter needle after withdrawal. Replace filter needle with sterile 30–gauge x 1/2-inch needle for intravitreal injection. Expel contents until plunger tip is aligned with line marking 0.05 mL on syringe Each vial should be used for only one eye. If contralateral eye requires treatment, use new vial and equipment. Refrigerate solution and protect from light; do not freeze.

Patient/Family Teaching

  • Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive to light, painful, or develops a change in vision.

Evaluation/Desired Outcomes

  • Slowing of vision loss.


a trademark for ranibizumab.
Mentioned in ?
References in periodicals archive ?
A Roche spokesperson told OT that it does not believe Avastin offers additional medical benefit over Lucentis or Eylea.
Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).
Osaka, Japan-based Santen said that the Phase 2a study is structured as a randomised, controlled trial that aims to establish the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis (ranibizumab) compared to Lucentis monotherapy in patients with wet AMD.
M2 EQUITYBITES-June 2, 2017-Samsung Bioepis to develop lower-cost copy of Roche eye drug Lucentis
A network of researchers found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes.
The FDA granted Lucentis Breakthrough Therapy Designation and Priority Review for this indication based on results from the RISE and RIDE Phase III clinical trials.
USPRwire, Sun Dec 14 2014] With the initial focus of biosimilar antibody developers very much sharpened on the markets for TNF inhibitors (Remicade, Humira) and leading cancer MAbs (Herceptin, Rituxan, Avastin), the opportunity for biosimilar Lucentis, for the treatment of wet age-related macular degeneration (AMD) has been very much overlooked.
6 billion) from the two companies for working together to push the cost of the jointly-marketed drug Lucentis higher.
After Italy's fine on Roche and Novartis for giving precedence to the costly drug Lucentis, BEUC wants to see the EU take strong action
The two companies collaborated to push their Lucentis medications, which blocks growth of abnormal blood vessels.
Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as macular degeneration.
Neovascular or wet age-related macular degeneration - known as Wet AMD - is normally treated with Lucentis.